SOTAGLIFLOZIN, A DUAL SGLT1/2 INHIBITOR, UNLIKE THE SELECTIVE SGLT2 INHIBITOR EMPAGLIFLOZIN, INHIBITS HUMAN PLATELET ACTIVATION AND IN VIVO THROMBUS FORMATION
Livia Stanger(University of Michigan), Michael Holinstat(University of Michigan), B. Pitt(University of Michigan)
Cited by 0
Related Papers
An age-progressive platelet differentiation path from hematopoietic stem cells causes exacerbated thrombosis
|Cell|2024|102
Protein Kinase C Regulation of 12-Lipoxygenase-Mediated Human Platelet Activation
|Molecular Pharmacology|2011|44
Antiplatelet strategies: past, present, and future
|Journal of Thrombosis and Haemostasis|2023|39
Irreversible Platelet Activation Requires Protease-Activated Receptor 1-Mediated Signaling to Phosphatidylinositol Phosphates
|Molecular Pharmacology|2009|36
DHA 12‐LOX‐derived oxylipins regulate platelet activation and thrombus formation through a PKA‐dependent signaling pathway
|Journal of Thrombosis and Haemostasis|2020|36